Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient.
An influenza B virus from an infant with no history of treatment or contact with neuraminidase inhibitors demonstrated a significant reduction in sensitivity to these drugs. Here, we describe the analysis of a mixed viral population that contained a novel D197E amino acid substitution that was responsible for this reduction.
Hurt
Aeron C
AC
WHO Collaborating Centre for Reference and Research on Influenza, 45 Poplar Rd., Parkville, Victoria 3052, Australia. Aeron.Hurt@influenzacentre.org
Iannello
Pina
P
Jachno
Kim
K
Komadina
Naomi
N
Hampson
Alan W
AW
Barr
Ian G
IG
McKimm-Breschkin
Jennifer L
JL
D000081:Acetamides / Q000494:pharmacology; D000146:Acids, Carbocyclic; D019943:Amino Acid Substitution; D000998:Antiviral Agents / Q000494:pharmacology; D016367:Baculoviridae / Q000235:genetics; D001483:Base Sequence; D003517:Cyclopentanes / Q000494:pharmacology; D024882:Drug Resistance, Viral / Q000235:genetics*; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006146:Guanidines / Q000494:pharmacology; D006801:Humans; D007223:Infant; D009981:Influenza B virus / Q000187:drug effects* / Q000302:isolation & purification; D007251:Influenza, Human / Q000188:drug therapy* / Q000821:virology; D020128:Inhibitory Concentration 50; D008826:Microbial Sensitivity Tests; D008969:Molecular Sequence Data; D009439:Neuraminidase / Q000037:antagonists & inhibitors* / Q000235:genetics; D053139:Oseltamivir; D011714:Pyrans / Q000494:pharmacology; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors; D012794:Sialic Acids / Q000494:pharmacology; D053243:Zanamivir
D000081:Acetamides; D000146:Acids, Carbocyclic; D000998:Antiviral Agents; D003517:Cyclopentanes; D004791:Enzyme Inhibitors; D006146:Guanidines; D011714:Pyrans; D011994:Recombinant Proteins; D012794:Sialic Acids; D053139:Oseltamivir; D009439:Neuraminidase; D053243:Zanamivir; C414210:peramivir